Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood filter could speed recovery for burn victims

NCT ID NCT07259668

Disease control Sponsor: Efferon JSC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a device called Efferon LPS that filters the blood to remove toxins and inflammatory substances in adults with severe thermal burns. Fifteen participants will receive two filtering sessions, and their outcomes will be compared to a group of similar patients from the past. The goal is to see if the device can shorten ICU stays and reduce the need for blood pressure medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Efferon LPS device (blood filter that removes toxins and inflammatory substances)
What this could lead to
If it works, this could point toward a way to reduce ICU stays and need for blood pressure support in severe burn patients.
What could go wrong
This is a very small pilot study (15 people) with no control group from the same time period, so results may not be reliable or generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with thermal burns undergoing treatment in State Novosibirsk Regional Clinical Hospital

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Thermal burn of Ⅱ and Ⅲ severity with a lesion area of 40% or more (ICD-10: T20-T25, T29) * Burn disease in the stage of acute toxemia or septicemia * Frank Index ≥ 90 (Frank Index quantifies burn severity based on the depth and total surface area of the skin lesion) * The patient's condition allows for Efferon LPS therapy for at least 6 hours Exclusion Criteria: * Isolated thermal inhalation injury * Charlson Comorbidity Index \> 8 * Dementia * End-stage renal failure * Acute pulmonary embolism confirmed by CT * Acute myocardial infarction within the past 4 weeks * Acute cerebrovascular accident * Uncontrolled bleeding (acute blood loss within the past 24 hours) * Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burns are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

burn

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Burns

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • State Novosibirsk Regional Clinical Hospital

    RECRUITING

    Novosibirsk, 630087, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.